This page shows the publications co-authored by Paul Ridker and Masanori Aikawa.
Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. PLoS One. 2014; 9(4):e94073.
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMa) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc Diabetol. 2019 06 04; 18(1):71.
Endophenotype Network Models: Common Core of Complex Diseases. Sci Rep. 2016 06 09; 6:27414.
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003 Oct 14; 108(15):1772-8.
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003 Oct 07; 108(14):1664-72.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.